Table 3.
Dose modifications and permanent drug discontinuation (ITT population).
| Dose interruptions, reductions, transfusions, and discontinuations | Talazoparib (N = 61) |
|---|---|
| Number (%) of patients | n (%) |
| Dose interruptions due to AEs | 20 (32.8) |
| Dose reductions due to AEs | 24 (39.3) |
| Packed red blood cell transfusion | 13 (21.3) |
| Transfusion | 7 (11.5) |
| Permanent drug discontinuation | |
| Adverse event | 3 (4.9) |
| Death | 0 |
| Progressive disease | 10 (16.4) |
| Withdrawal by patienta | 2 (3.3) |
| Otherb | 1 (1.6) |
Abbreviations: AE, adverse event; ITT, intent-to-treat.
aOne patient completed only 4 months of treatment and decided to have surgery early and 1 patient withdrew consent from the treatment and also permanently discontinued from the study.
bPatient had surgery early in another country and specimen was not provided to central laboratory.